Search - tctmd.com

Displaying 81 - 100 of 648

Sort: Relevancy | Date

Presentation THT 2025

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Presenter: Stavros Drakos

February 12, 2025

Presentation THT 2025

Proactive Medical Management: GDMT & Diuretic Strategies Based on PA Pressure, Vital Signs, and Symptoms

Presenter: Michael Kiernan

February 12, 2025

Presentation THT 2025

Rationale for Mineralocorticoid Receptor Blockade with Finerenone in HF

Presenter: Carolyn Lam

February 12, 2025

Presentation THT 2025

DOACS in LVAD: Should We, Should We Not?

Presenter: Palak Shah

February 12, 2025

Presentation THT 2025

Medical Management (Heparin/ Lytics)

Presenter: Gregory Piazza

February 12, 2025

Presentation THT 2025

The HF Physician's Approach: GDMT - Give the Darn Medicines a Try!

Presenter: Ryan Tedford

February 12, 2025

Presentation THT 2025

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 12, 2025

Presentation THT 2025

When and Why Are Diuretics Sometimes Just Not Enough?

Presenter: Jennifer Cowger

February 12, 2025

Presentation THT Abstracts 2025

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector

Presenter: John Mohr

February 11, 2025

Presentation THT Abstracts 2025

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Presenter: Stavros Drakos

February 11, 2025

Presentation THT 2025

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector

Presenter: John Mohr

February 11, 2025

Presentation THT 2025

Emerging Therapies Targeting Inflammation and Metabolic Dysfunction in Heart Failure

Presenter: Mark Petrie

February 11, 2025

News Opinion CV Team Dispatch

February 2025 Dispatch for the CV Team

L.A. McKeown

February 01, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Societies Update Appropriate Use Criteria for Cardiac Implantable Devices

Todd Neale

January 23, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Features

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Michael O'Riordan

January 17, 2025

News Daily News

Vascular Disease History Need Not Preclude Aspirin Withdrawal After HeartMate 3

Yael L. Maxwell

January 15, 2025

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

News Opinion Editor's Corner

TCTMD’s Biggest News of 2024: Stories, Videos, and More

Shelley Wood

January 01, 2025

Advertisement

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Proactive Medical Management: GDMT & Diuretic Strategies Based on PA Pressure, Vital Signs, and Symptoms

Rationale for Mineralocorticoid Receptor Blockade with Finerenone in HF

DOACS in LVAD: Should We, Should We Not?

Medical Management (Heparin/ Lytics)

The HF Physician's Approach: GDMT - Give the Darn Medicines a Try!

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

When and Why Are Diuretics Sometimes Just Not Enough?

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of Furosemide (FUR) Administered via an Autoinjector

Emerging Therapies Targeting Inflammation and Metabolic Dysfunction in Heart Failure

February 2025 Dispatch for the CV Team

January 2025 Dispatch for the CV Team

Societies Update Appropriate Use Criteria for Cardiac Implantable Devices

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Vascular Disease History Need Not Preclude Aspirin Withdrawal After HeartMate 3

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

TCTMD’s Biggest News of 2024: Stories, Videos, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content